How India Exports Artemether to the World

Artemether, an antimalarial agent, is not currently listed in the FDA's Orange Book, indicating the absence of approved Abbreviated New Drug Applications (ANDAs) for this compound in the United States. Consequently, there are no recent approvals or import alerts specific to artemether. The regulatory pathway for introducing artemether into the U.S. market would necessitate the submission of a New Drug Application (NDA) or ANDA, adhering to the FDA's stringent requirements for demonstrating safety, efficacy, and manufacturing quality.

Given that 481 Indian exporters are actively involved in the global distribution of artemether, the absence of FDA approvals suggests a potential opportunity for these manufacturers to explore the U.S. market. However, this would require substantial investment in clinical trials and regulatory compliance to meet FDA standards.

In the European Union, the combination of artemether and lumefantrine has been subject to periodic safety update report single assessments (PSUSAs) by the European Medicines Agency (EMA). Notably, in October 2022, the EMA conducted a PSUSA for artemether/lumefantrine, resulting in a maintenance outcome, indicating continued monitoring without immediate regulatory changes. (ema.europa.eu)

The United Kingdom, post-Brexit, has established its own regulatory framework through the Medicines and Healthcare products Regulatory Agency (MHRA). While specific actions regarding artemether are not detailed in the provided information, the MHRA generally aligns with EMA standards, requiring comprehensive data on quality, safety, and efficacy for marketing authorization.

Artemether is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in treating malaria. The WHO Prequalification Programme evaluates medicines to ensure they meet global standards of quality, safety, and efficacy, facilitating their procurement by UN agencies and member states. Artemether formulations are subject to these evaluations, promoting consistent quality across international markets.

Pharmacopoeial standards for artemether are established in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards provide detailed specifications for the identity, purity, and potency of artemether, ensuring uniformity in its production and quality control.

In India, artemether is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines; however, specific ceiling prices for artemether are not detailed in the provided information. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The primary patents for artemether have expired, leading to increased generic competition globally. This competitive landscape is reflected in India's export data, where 481 exporters are actively supplying artemether to 107 destination countries. The top five exporters—IPCA Laboratories Limited, Macleods Pharmaceuticals Ltd, Innova Captab Limited, Mylan Laboratories Limited, and Strides Pharma Science Limited—collectively account for a significant share of the $897.9 million USD total export value.

In August 2023, the EMA adopted a positive opinion for the marketing authorization of Artesunate Amivas, an injectable formulation for severe malaria, highlighting ongoing regulatory activities in the antimalarial sector. (ema.europa.eu)

In October 2022, the EMA conducted a PSUSA for artemether/lumefantrine, resulting in a maintenance outcome, indicating continued monitoring without immediate regulatory changes. (ema.europa.eu)

In January 2020, the EMA granted orphan designation to artesunate for the treatment of malaria, reflecting ongoing efforts to address unmet medical needs in this area. (ema.europa.eu)

These developments underscore the dynamic regulatory environment surrounding antimalarial therapies, with implications for manufacturers and exporters of artemether.

India's pharmaceutical industry, including the production of Artemether, heavily relies on Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) imported from China. Approximately 60–70% of India's API and KSM requirements are sourced from China, creating a significant supply chain vulnerability. This dependency exposes the supply chain to risks such as geopolitical tensions, trade restrictions, and production disruptions in China.

To mitigate these risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to boost domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, the scheme has led to the establishment of manufacturing capacity for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. While these initiatives are steps toward reducing dependency, the transition to self-sufficiency is ongoing, and the supply chain remains susceptible to external disruptions.

The export market for Artemether from India is highly concentrated, with the top five exporters accounting for 82.2% of total exports. IPCA Laboratories Limited alone holds a dominant 69.9% share, exporting Artemether worth $627.8 million. This high concentration poses a significant single-source risk; any operational or compliance issues at IPCA could severely disrupt the global supply of Artemether.

The PLI scheme for bulk drugs, initiated in July 2020, aims to diversify the supplier base by encouraging more manufacturers to produce critical APIs and KSMs domestically. The scheme has a financial outlay of ₹6,940 crore and covers 41 products, including key starting materials, drug intermediates, and active pharmaceutical ingredients. However, the impact of this scheme on Artemether production is yet to be fully realized, and the current supplier concentration continues to pose a risk to supply chain stability.

Global shipping routes, particularly the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceuticals. Disruptions in these areas due to geopolitical tensions or conflicts can lead to delays and increased costs in the supply chain. Additionally, ongoing U.S.-China trade tensions have the potential to impact the availability and pricing of APIs and KSMs sourced from China, further exacerbating supply chain vulnerabilities.

Regulatory bodies such as the FDA and EMA have issued shortage alerts for various pharmaceuticals in recent years, highlighting the fragility of the global supply chain. While specific alerts for Artemether have not been prominent, the interconnected nature of pharmaceutical supply chains means that disruptions in one area can have cascading effects on others.

• Diversify Supplier Base: Encourage the development of additional Artemether manufacturers to reduce reliance on a single supplier and enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme to boost domestic production of Artemether and its KSMs, reducing dependency on imports.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the sourcing and movement of APIs and KSMs, allowing for proactive identification and mitigation of potential disruptions.

• Develop Strategic Reserves: Establish reserves of critical APIs and KSMs to buffer against short-term supply disruptions caused by geopolitical events or shipping delays.

• Foster International Collaboration: Engage in partnerships with other countries to develop alternative sources for KSMs and APIs, thereby reducing dependency on any single nation.

RISK_LEVEL: MEDIUM